Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 06/12/2025 am IST			5-day change	1st Jan Change
22.26 ^USD	-2.45%		+4.31%	-81.69%

25/11	Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI
25/11	Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy	MT

Analyst Reco.

Sarepta Therapeutics Shares Rise After Mizuho Upgrade	06/11	MT
Mizuho Securities Upgrades Sarepta Therapeutics to Outperform From Neutral, Adjusts PT to $26 From $19	05/11	MT
BofA Securities Adjusts Sarepta Therapeutics Price Target to $18 From $16, Maintains Underperform Rating	22/10	MT
RBC Raises Price Target on Sarepta Therapeutics to $16 From $14, Keeps Sector Perform, Speculative Risk	08/10	MT
BMO Capital Upgrades Sarepta Therapeutics to Outperform From Market Perform, Price Target is $50	22/09	MT
BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating	20/08	MT
Sarepta Therapeutics Still Faces Elevidys Demand Uncertainty, Deutsche Bank Says	15/08	MT
Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $12 From $6, Maintains Sell Rating	15/08	MT
Analyst recommendations: Amgen, Applied Materials, Cisco, Nvidia, Oracle…	15/08
Barclays Upgrades Sarepta Therapeutics to Equalweight From Underweight, Raises Price Target to $22 From $10	29/07	MT
Sarepta Therapeutics Set to Trade Higher With Elevidys Back on Market, Oppenheimer Says	29/07	MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Market Perform, Adjusts Price Target to $37 From $30	29/07	MT
JPMorgan Upgrades Sarepta Therapeutics to Neutral From Underweight, Price Target is $24	29/07	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $20 From $15, Keeps Equalweight Rating	29/07	MT
JPMorgan Downgrades Sarepta Therapeutics to Underweight From Neutral	28/07	MT
Barclays Downgrades Sarepta Therapeutics to Underweight From Equalweight, Adjusts Price Target to $10 From $18	28/07	MT
Swiss stocks - Factors to watch on July 28	28/07	RE
Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $6 From $9, Maintains Sell Rating	25/07	MT
BofA Downgrades Sarepta Therapeutics to Underperform From Neutral, Price Target is $10	23/07	MT
Barclays Downgrades Sarepta Therapeutics to Equalweight From Overweight, Adjusts Price Target to $18 From $32	22/07	MT
Sector Update: Health Care Stocks Softer Late Afternoon	22/07	MT
Leerink Partners Downgrades Sarepta Therapeutics to Perform From Outperform, Adjusts Price Target to $10 From $45	21/07	MT
Mizuho Securities Downgrades Sarepta Therapeutics to Neutral From Outperform, Adjusts Prices Target to $14 From $40	21/07	MT
Deutsche Bank Downgrades Sarepta Therapeutics to Sell From Hold, Adjusts Price Target to $9 From $25	21/07	MT
Baird Downgrades Sarepta Therapeutics to Neutral From Outperform, $15 Price Target; Shares Fall	19/07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Analyst Reco.

Filters